0001070081-19-000061.txt : 20191226
0001070081-19-000061.hdr.sgml : 20191226
20191226172432
ACCESSION NUMBER: 0001070081-19-000061
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191223
FILED AS OF DATE: 20191226
DATE AS OF CHANGE: 20191226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Souza Marcio
CENTRAL INDEX KEY: 0001707657
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35969
FILM NUMBER: 191311144
MAIL ADDRESS:
STREET 1: C/O PTC THERAPEUTICS, INC.
STREET 2: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001070081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043416587
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
BUSINESS PHONE: 9082227000
MAIL ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
FORMER COMPANY:
FORMER CONFORMED NAME: PTC THERAPEUTICS INC
DATE OF NAME CHANGE: 19980909
4
1
wf-form4_157739905265156.xml
FORM 4
X0306
4
2019-12-23
0
0001070081
PTC THERAPEUTICS, INC.
PTCT
0001707657
Souza Marcio
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD
NJ
07080
0
1
0
0
Chief Operating Officer
Common Stock
2019-12-23
4
S
0
6000
48.322
D
53035
D
Common Stock
2019-12-23
4
S
0
14814
49.141
D
38221
D
Common Stock
2019-12-23
4
M
0
30000
12.53
A
68221
D
Common Stock
2019-12-23
4
S
0
8729
48.321
D
59492
D
Common Stock
2019-12-23
4
S
0
21271
49.14
D
38221
D
Common Stock
2019-12-23
4
M
0
15881
11.23
A
54102
D
Common Stock
2019-12-23
4
S
0
8877
48.58
D
45225
D
Common Stock
2019-12-23
4
S
0
7004
49.319
D
38221
D
Common Stock
2019-12-23
4
M
0
30000
18.01
A
68221
D
Common Stock
2019-12-23
4
S
0
11332
48.431
D
56889
D
Common Stock
2019-12-23
4
S
0
18668
49.19
D
38221
D
Common Stock
2019-12-23
4
M
0
6250
12.92
A
11288
I
By Spouse
Common Stock
2019-12-23
4
S
0
6250
48.80
D
5038
I
By Spouse
Stock Option (Right To Buy)
12.53
2019-12-23
4
M
0
30000
12.53
D
2027-05-30
Common Stock
30000.0
0
D
Stock Option (Right To Buy)
11.23
2019-12-23
4
M
0
15881
11.23
D
2027-01-02
Common Stock
15881.0
7219
D
Stock Option (Right To Buy)
18.01
2019-12-23
4
M
0
30000
18.01
D
2028-01-02
Common Stock
30000.0
45000
D
Stock Option (Right To Buy)
12.92
2019-12-23
4
M
0
6250
12.92
D
2027-05-17
Common Stock
6250.0
3750
I
By Spouse
Stock Option (Right To Buy)
33.02
2029-01-21
Common Stock
112500.0
112500
D
Stock Option (Right To Buy)
33.02
2029-01-21
Common Stock
25000.0
25000
D
Stock Option (Right To Buy)
26.42
2024-07-31
Common Stock
30000.0
30000
D
Stock Option (Right To Buy)
51.0
2025-01-02
Common Stock
10525.0
10525
D
Stock Option (Right To Buy)
30.86
2026-01-03
Common Stock
16000.0
16000
D
Stock Option (Right To Buy)
12.64
2026-11-16
Common Stock
2000.0
2000
D
Stock Option (Right To Buy)
33.02
2029-01-21
Common Stock
6825.0
6825
I
By Spouse
Stock Option (Right To Buy)
18.01
2028-01-02
Common Stock
2696.0
2696
I
By Spouse
The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.75 to $48.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Includes 371 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2019.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.77 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.77 to $48.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.02 to $49.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $49.03 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.82 to $48.82 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.82 to $49.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The transactions of the Reporting Person's spouse reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on November 19, 2019.
Currently exerciseable.
This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018.
This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
This option was granted on November 17, 2016, and vests over four years, with 25% of the shares underlying the option vesting on November 17, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on February 17, 2018.
Avraham S. Adler, attorney-in-fact
2019-12-26